AU2017315076B2 - Anti-VEGF-A antibodies and uses thereof - Google Patents

Anti-VEGF-A antibodies and uses thereof Download PDF

Info

Publication number
AU2017315076B2
AU2017315076B2 AU2017315076A AU2017315076A AU2017315076B2 AU 2017315076 B2 AU2017315076 B2 AU 2017315076B2 AU 2017315076 A AU2017315076 A AU 2017315076A AU 2017315076 A AU2017315076 A AU 2017315076A AU 2017315076 B2 AU2017315076 B2 AU 2017315076B2
Authority
AU
Australia
Prior art keywords
antibody
binding
amino acid
acid sequence
lcdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017315076A
Other languages
English (en)
Other versions
AU2017315076A1 (en
Inventor
Mario A. Cepeda
Karen Coffman
Nazzareno Dimasi
Changshou Gao
Ching Ching Leow
Adrian Schwartz Mittelman
Ping Tsui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of AU2017315076A1 publication Critical patent/AU2017315076A1/en
Application granted granted Critical
Publication of AU2017315076B2 publication Critical patent/AU2017315076B2/en
Priority to AU2020289850A priority Critical patent/AU2020289850B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2017315076A 2016-08-23 2017-08-22 Anti-VEGF-A antibodies and uses thereof Active AU2017315076B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020289850A AU2020289850B2 (en) 2016-08-23 2020-12-18 Anti-vegf-a antibodies and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378391P 2016-08-23 2016-08-23
US62/378,391 2016-08-23
PCT/EP2017/071106 WO2018037001A1 (en) 2016-08-23 2017-08-22 Anti-vegf-a antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020289850A Division AU2020289850B2 (en) 2016-08-23 2020-12-18 Anti-vegf-a antibodies and uses thereof

Publications (2)

Publication Number Publication Date
AU2017315076A1 AU2017315076A1 (en) 2019-04-04
AU2017315076B2 true AU2017315076B2 (en) 2020-10-08

Family

ID=59677248

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017315076A Active AU2017315076B2 (en) 2016-08-23 2017-08-22 Anti-VEGF-A antibodies and uses thereof
AU2020289850A Active AU2020289850B2 (en) 2016-08-23 2020-12-18 Anti-vegf-a antibodies and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020289850A Active AU2020289850B2 (en) 2016-08-23 2020-12-18 Anti-vegf-a antibodies and uses thereof

Country Status (10)

Country Link
US (2) US10919958B2 (enExample)
EP (2) EP3783022A3 (enExample)
JP (2) JP6949106B2 (enExample)
KR (1) KR102538827B1 (enExample)
CN (1) CN109863172B (enExample)
AU (2) AU2017315076B2 (enExample)
CA (1) CA3034576A1 (enExample)
ES (1) ES2836286T3 (enExample)
IL (1) IL264961B2 (enExample)
WO (1) WO2018037001A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7485273B2 (ja) * 2020-06-25 2024-05-16 国立大学法人 鹿児島大学 抗ｖｅｇｆ－ａ抗体による癌に対する治療応答性を予測又は決定するための方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045331A2 (en) * 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
WO2009120922A2 (en) * 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
EP2338915A3 (en) * 1997-04-07 2011-10-12 Genentech, Inc. Anti-VEGF antibodies
KR100787073B1 (ko) 2000-06-28 2007-12-21 글리코파이, 인크. 변형된 당단백질의 제조방법
WO2007084922A2 (en) 2006-01-17 2007-07-26 Biolex Therapeutics, Inc. Compositions and methods for humanization and optimization of n-glycans in plants
US20110076279A1 (en) * 2006-10-20 2011-03-31 Schering Corporation Fully human anti-vegf antibodies and methods of using
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
WO2010124009A2 (en) * 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
CN102276722B (zh) * 2011-01-14 2013-05-08 中国科学院北京基因组研究所 新型血管内皮生长因子人源化单克隆抗体
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
ES2749349T3 (es) * 2011-11-07 2020-03-19 Medimmune Llc Proteínas de unión multiespecíficas y multivalentes y usos de las mismas

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045331A2 (en) * 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
WO2009120922A2 (en) * 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHENGZHONG CAI ET AL, "Differential Expression of VEGF 121, VEGF 165 and VEGF 189 in Angiomas and Squamous Cell Carcinoma Cell Lines of the Head and Neck", ANTICANCER RESEARCH, (2010-03-01), vol. 30, pages 805 - 810 *
KLAUS PODAR ET AL, "The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications", BLOOD, (2004-10-07), vol. 105, doi:10.1182/blood-2004-, pages 1383 - 1395 *
MOHAMED MUHSIN ET AL, "Fresh from the pipeline: Bevacizumab", NATURE REVIEWS. DRUG DISCOVERY, GB, (2004-12-01), vol. 3, no. 12, doi:10.1038/nrd1601, ISSN 1474-1776, pages 995 - 996 *
STEPHAN DUEBEL ED - STEFAN DÜBEL, Handbook of Therapeutic Antibodies Chapter 6, HANDBOOK OF THERAPEUTIC ANTIBO, WILEY-VCH, WEINHEIM, PAGE(S) 119 - 144, (2007-01-01), ISBN 978-3-527-31453-9 *

Also Published As

Publication number Publication date
EP3504236B1 (en) 2020-09-23
JP2019528074A (ja) 2019-10-10
AU2020289850A1 (en) 2021-01-28
US10919958B2 (en) 2021-02-16
JP7277531B2 (ja) 2023-05-19
AU2020289850B2 (en) 2024-06-06
JP6949106B2 (ja) 2021-10-13
CN109863172B (zh) 2022-08-26
US11634483B2 (en) 2023-04-25
KR20190040029A (ko) 2019-04-16
AU2017315076A1 (en) 2019-04-04
EP3783022A2 (en) 2021-02-24
IL264961B2 (en) 2025-02-01
JP2022008447A (ja) 2022-01-13
EP3783022A3 (en) 2021-06-30
CN109863172A (zh) 2019-06-07
IL264961A (enExample) 2019-04-30
IL264961B1 (en) 2024-10-01
US20210147531A1 (en) 2021-05-20
CA3034576A1 (en) 2018-03-01
US20190202903A1 (en) 2019-07-04
KR102538827B1 (ko) 2023-05-31
WO2018037001A1 (en) 2018-03-01
ES2836286T3 (es) 2021-06-24
EP3504236A1 (en) 2019-07-03

Similar Documents

Publication Publication Date Title
US11566068B2 (en) Nucleic acids encoding bispecific anti-VEGF and anti-ANG2 antibodies and uses thereof
RS63063B1 (sr) Anti-ngf antitela i njihova upotreba
CN106905431B (zh) 抗人补体d因子的单克隆抗体及其用途
KR20180068952A (ko) 신규한 항-인간 gpvi 항체 및 이의 용도
US11634483B2 (en) Nucleic acids encoding anti-VEGF-A antibodies and uses thereof
HK40047851A (en) Anti-vegf-a antibodies and uses thereof
HK40010498B (en) Anti-vegf-a antibodies and uses thereof
HK40010498A (en) Anti-vegf-a antibodies and uses thereof
HK40008333B (en) Anti-vegf-a antibodies and uses thereof
HK40008333A (en) Anti-vegf-a antibodies and uses thereof
CN119751677A (zh) Anti-CD19 CAR表达检测的抗独特型抗体
HK40008334A (en) Anti-vegf-a and anti-ang2 antibodies and uses thereof
HK40008334B (zh) 抗vegf-a和抗ang2抗体及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)